Gina Fagan

Gina Fagan has extensive experience in the pharmaceutical industry, with over 30 years of experience in various roles related to drug safety and pharmacovigilance. Gina began their career at Bristol-Myers Squibb, where they worked as a Regulatory Associate in Drug Safety and later as a Manager of Drug Information. Gina then moved on to roles at Janssen Pharmaceutica, Abbott Laboratories, Bayer Pharmaceuticals, and Forest Laboratories, where they continued to gain experience in drug safety and pharmacovigilance management. In 2001, they joined Novartis as the Director of Clinical Quality Assurance before transitioning to NPS Pharmaceuticals, where they served as the Head of Clinical Drug Safety and Pharmacovigilance. After their time at NPS Pharmaceuticals, Gina joined Novartis Consumer Health as the Director of Global Case Processing, where they managed a global team responsible for collecting, processing, and reporting on company reports on NCH products. Gina also participated in EMEA inspections and had responsibilities related to process improvement, SOPs, and training. In 2010, Gina joined Upsher-Smith Laboratories as the Director of Clinical Safety. Gina'smost recent position was at Progenics Pharmaceuticals, Inc., where they held the roles of Director and Senior Director in Medical Information, Drug Safety, and Pharmacovigilance Operations. Throughout their career, Gina has demonstrated a strong ability to manage teams, oversee safety processes, and collaborate with internal and external stakeholders.

Gina Fagan's education history begins in 1978 when they enrolled at Monmouth University. Gina pursued a Bachelor of Science degree in Biology and completed their studies in 1982.

Following this, from 1984 to 1987, Gina attended Rutgers Robert Wood Johnson Medical School. Gina focused on Physician Assistant studies and earned a Bachelor of Science degree in this field.

It is important to note that no other information beyond Gina's education history is provided.